AU2011342904B2 - Cell culture medium - Google Patents

Cell culture medium Download PDF

Info

Publication number
AU2011342904B2
AU2011342904B2 AU2011342904A AU2011342904A AU2011342904B2 AU 2011342904 B2 AU2011342904 B2 AU 2011342904B2 AU 2011342904 A AU2011342904 A AU 2011342904A AU 2011342904 A AU2011342904 A AU 2011342904A AU 2011342904 B2 AU2011342904 B2 AU 2011342904B2
Authority
AU
Australia
Prior art keywords
laminin
cells
cell culture
cell
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011342904A
Other languages
English (en)
Other versions
AU2011342904A1 (en
Inventor
Sergey Rodin
Karl Tryggvason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolamina AB
Original Assignee
Biolamina AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolamina AB filed Critical Biolamina AB
Publication of AU2011342904A1 publication Critical patent/AU2011342904A1/en
Application granted granted Critical
Publication of AU2011342904B2 publication Critical patent/AU2011342904B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011342904A 2010-12-17 2011-12-16 Cell culture medium Active AU2011342904B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201061424273P 2010-12-17 2010-12-17
US61/424,273 2010-12-17
US201161488353P 2011-05-20 2011-05-20
US61/488,353 2011-05-20
US201161533063P 2011-09-09 2011-09-09
US61/533,063 2011-09-09
US201161537940P 2011-09-22 2011-09-22
US61/537,940 2011-09-22
US201161565380P 2011-11-30 2011-11-30
US61/565,380 2011-11-30
US201161565849P 2011-12-01 2011-12-01
US61/565,849 2011-12-01
PCT/IB2011/003265 WO2012080844A1 (en) 2010-12-17 2011-12-16 Cell culture medium

Publications (2)

Publication Number Publication Date
AU2011342904A1 AU2011342904A1 (en) 2013-08-08
AU2011342904B2 true AU2011342904B2 (en) 2016-05-12

Family

ID=45755415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011342904A Active AU2011342904B2 (en) 2010-12-17 2011-12-16 Cell culture medium

Country Status (12)

Country Link
US (2) US10138292B2 (https=)
EP (2) EP2651973B1 (https=)
JP (2) JP6002675B2 (https=)
KR (3) KR101966033B1 (https=)
CN (2) CN103384680B (https=)
AU (1) AU2011342904B2 (https=)
BR (2) BR112013017629A2 (https=)
CA (2) CA2826252C (https=)
IL (2) IL226971B (https=)
MX (2) MX343462B (https=)
SG (3) SG10201510405PA (https=)
WO (2) WO2012080844A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
CN103384680B (zh) 2010-12-17 2015-08-26 拜奥拉米那公司 细胞培养基
AU2012311233B2 (en) * 2011-09-22 2017-03-16 Sergey Rodin Cell culture substrate comprising a laminin and a cadherin
WO2013080051A2 (en) 2011-11-30 2013-06-06 Biolamina Ab Methods of enhancing genetic diagnosis
WO2013156855A1 (en) 2012-04-20 2013-10-24 Biolamina Ab Maintenance of differentiated cells with laminins
US20130330825A1 (en) * 2012-06-07 2013-12-12 City Of Hope Attachment substrates for directed differentiation of human embryonic stem cells in culture
DK2892996T3 (da) * 2012-09-07 2019-10-07 Biolamina Ab Stamcellebank
EP2925856B1 (en) 2012-12-03 2018-03-07 Biolamina AB Methods of producing rpe cells
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
EP3546568A3 (en) 2013-07-02 2019-10-23 National University of Singapore Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins ln-511, ln-521 and ln-221
EP3064572B1 (en) * 2013-11-01 2020-02-12 BBHC Co. Ltd. Method for producing induced pluripotent stem cell from mesenchymal stem cell and induced pluripotent stem cell produced by the method
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
EP3213761B1 (en) * 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
CN121891508A (zh) * 2014-10-31 2026-04-21 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
ES2703167T5 (es) 2015-02-20 2022-09-30 Inst Nat Sante Rech Med Uso de una laminina para diferenciar células pluripotentes en células de linaje hepatocitario
WO2017034459A1 (en) * 2015-08-23 2017-03-02 Diamyd Medical Ab New use
WO2017072580A1 (en) * 2015-10-30 2017-05-04 Biolamina Ab Methods for producing hepatocytes
WO2017082026A1 (ja) * 2015-11-10 2017-05-18 日機装株式会社 細胞支持複合体および細胞支持複合体の製造方法
CN116121189A (zh) 2016-03-30 2023-05-16 阿斯特利亚斯生物治疗股份公司 少突胶质细胞祖细胞组合物
US20190211305A1 (en) * 2016-08-25 2019-07-11 Kyoto University Method for Culturing Pluripotent Stem Cells on Specific Laminin
SG11201903428XA (en) 2016-11-16 2019-05-30 Cynata Therapeutics Ltd Pluripotent stem cell assay
CN106591295B (zh) * 2016-12-31 2019-10-25 贵州北科生物科技有限公司 一种多功能干细胞培养方法及所用培养基
WO2018203834A1 (en) 2017-05-05 2018-11-08 National University Of Singapore Methods for culturing human keratinocytes
IL281628B2 (en) 2018-09-19 2025-06-01 Lineage Cell Therapeutics Inc Methods for differentiating pluripotent stem cells in dynamic suspension culture
WO2020154533A1 (en) 2019-01-23 2020-07-30 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN111617105A (zh) * 2019-04-03 2020-09-04 成熙(上海)生物科技有限公司 一种脂肪干细胞多细胞活性因子冻干粉的制备方法
CN111621473A (zh) * 2019-04-03 2020-09-04 成熙(上海)生物科技有限公司 一种新型人源脂肪干细胞制剂的制备方法
WO2021233116A1 (zh) * 2020-05-21 2021-11-25 北京大学 多能干细胞的成分明确、无异源的培养系统
CN111569048B (zh) * 2020-05-22 2023-04-18 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 LamG5肽在制备修复睾丸中支持细胞损伤的药物中的应用
WO2025067551A1 (zh) * 2024-05-16 2025-04-03 北京百普赛斯生物科技股份有限公司 活性增强的改造型Laminin 521蛋白及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005252B1 (en) * 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
ES2705683T3 (es) * 2002-12-16 2019-03-26 Technion Res & Dev Foundation Medio de cultivo de células madre pluripotentes
CN101052712A (zh) * 2004-09-08 2007-10-10 威斯康星校友研究基金会 培养人胚胎干细胞
JP2006087396A (ja) 2004-09-27 2006-04-06 National Institute For Environmental Studies 細胞培養基質及びその製造方法
CN101180388A (zh) * 2005-11-18 2008-05-14 银怎株式会社 用于胚胎干细胞未分化增殖的包括大田软海绵酸的组合物
KR20080109775A (ko) * 2006-02-23 2008-12-17 노보셀, 인크 분화가능한 세포를 배양하는데 유용한 조성물 및 방법
CN101605885B (zh) 2007-01-04 2013-03-27 卡尔·特吕格瓦松 能够使多能干细胞增殖的组合物及方法
US10829733B2 (en) * 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
US8951799B2 (en) * 2007-01-04 2015-02-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent stem cells
BRPI0813787A2 (pt) 2007-07-01 2014-10-07 Lifescan Inc Cultura de célula-tronco pluripotente isolada
SG188904A1 (en) * 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
JP5464443B2 (ja) * 2008-03-31 2014-04-09 オリエンタル酵母工業株式会社 多能性幹細胞を増殖させる方法
EP2315827A1 (en) 2008-07-07 2011-05-04 Mass Institute Of Technology Micropatterned co-culture systems as infectious disease analysis platforms
WO2010137746A1 (en) 2009-05-29 2010-12-02 Kyoto University Method for producing induced pluripotent stem cells and method for culturing the same
JP5700301B2 (ja) * 2009-06-03 2015-04-15 国立大学法人大阪大学 多能性幹細胞からの神経堤細胞群の分化誘導方法
CA2707296A1 (en) 2009-06-12 2010-12-12 Richard T. Scott, Jr. Method for relative quantitation of chromosomal dna copy number in a single or few cells
CN103384680B (zh) 2010-12-17 2015-08-26 拜奥拉米那公司 细胞培养基

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NISHIUCHI et al:Matrix Biology. 2006;25(3):189-197 *
RODIN et al: "Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511" Nature Biotech; 2010;28(6):611 *
UNGER C. et al: "Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells." Human Reproduction. 2009;24(10):2567-2581 *
WANG et al: "Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells.", J. Biologica Chem. 2009;284(49):34054-34064 *
WANG G et al: "Noggin and bFGF cooperate to maintain the pluripotency of human embryonic stem cells in the absence of feeder layers", Biochemical Biophysical Res Comm. 2005;330(3):934-942 *

Also Published As

Publication number Publication date
KR101921350B1 (ko) 2018-11-22
MX343462B (es) 2016-11-07
JP6002675B2 (ja) 2016-10-05
MX345861B (es) 2017-02-20
SG10201510405PA (en) 2016-01-28
US20120156254A1 (en) 2012-06-21
CA2828794A1 (en) 2012-06-21
SG191216A1 (en) 2013-07-31
KR20190018024A (ko) 2019-02-20
CA2826252C (en) 2018-12-04
JP5990531B2 (ja) 2016-09-14
WO2012080844A1 (en) 2012-06-21
JP2014501101A (ja) 2014-01-20
BR112013017632A2 (pt) 2016-10-11
CA2826252A1 (en) 2012-06-21
CN103384679B (zh) 2015-08-26
WO2012080842A1 (en) 2012-06-21
KR20140016881A (ko) 2014-02-10
EP2651973B1 (en) 2016-08-31
CN103384679A (zh) 2013-11-06
SG191215A1 (en) 2013-07-31
MX2013006958A (es) 2013-12-16
BR112013017629A2 (pt) 2017-04-18
US10138292B2 (en) 2018-11-27
US20120156782A1 (en) 2012-06-21
CN103384680B (zh) 2015-08-26
US8415156B2 (en) 2013-04-09
EP2651974A1 (en) 2013-10-23
EP2651973A1 (en) 2013-10-23
JP2013545489A (ja) 2013-12-26
KR20140012047A (ko) 2014-01-29
EP2651974B1 (en) 2015-09-16
MX2013006959A (es) 2013-12-06
IL226971B (en) 2018-04-30
IL270186B (en) 2020-08-31
KR101966033B1 (ko) 2019-04-04
CA2828794C (en) 2021-07-13
CN103384680A (zh) 2013-11-06

Similar Documents

Publication Publication Date Title
AU2011342904B2 (en) Cell culture medium
US12195757B2 (en) Methods of producing RPE cells
AU2017204108B2 (en) Cell culture medium
AU2011342904A1 (en) Cell culture medium
AU2016213884B2 (en) Recombinant laminin-511
AU2011342902B2 (en) Recombinant laminin-521
US9828630B2 (en) Methods of enhancing genetic diagnosis
AU2011342902A1 (en) Recombinant laminin-521

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)